We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Hold on to NEOGEN (NEOG) Stock for Now
Read MoreHide Full Article
NEOGEN Corporation (NEOG - Free Report) is well poised for growth in the coming quarters, backed by its slew of product launches and collaborations. Strong revenues in fiscal third quarter of 2021, along with its impressive international performance, buoy optimism. However, downsides may result from persistent pandemic-led business disruptions and a stiff competitive landscape.
Over the past year, the Zacks Rank #3 (Hold) stock has gained 52.4% compared with 20.6% growth of the industry and 51.7% rise of the S&P 500.
The renowned food and animal safety products provider has a market capitalization of $4.88 billion. The company projects 10% growth for the next five years and expects to maintain strong segmental performance. The company surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average surprise being 0.20%.
Let’s delve deeper.
Strong Q3 Results: NEOGEN’s impressive revenue performance in the third quarter of fiscal 2021 buoys optimism. The company’s segmental performance was primarily boosted by enhanced sales of cleaners and disinfectants to meet requirements created by the coronavirus pandemic. NEOGEN’s international performance was impressive as well, despite the challenging global business climate.
Acquisitions of international distributors and Megazyme, a food-quality diagnostics company, also contributed to growth. Expansion of both margins looks encouraging.
Product Launches: We are upbeat about the slew of product launches by NEOGEN over the recent months. The company, in February, relaunched its popular ThyroKare (levothyroxine sodium tablets), USP, which are approved by the FDA for replacement therapy for diminished thyroid function in dogs. During the same month, the company launched Early Warning COVID-19 Testing for wastewater.
In January, NEOGEN announced the launch of Reveal Q+ for the Aflatoxin M1 test — a faster and easier test to detect the presence of cancer-causing toxin aflatoxin M1.
Partnerships and Acquisitions: We are optimistic about the series of partnership and buyout deals inked by NEOGEN of late. The company, in January, acquired Ireland-based Megazyme, Ltd. — a major supplier of analytical solutions used by quality control laboratories in the global food and beverage industry.
NEOGEN entered into a partnership with Transnetyx, Inc. in November 2020 to collaborate on distribution and advancement of the miniMUGA genotyping array (Mouse Universal Genotyping Array).
Downsides
Persistent Coronavirus Concerns: NEOGEN continues to be adversely impacted by the pandemic-led global market disruptions, especially in the food industry, in some of its important end markets in the United States and Europe due to still-in-place lockdowns and social-distancing restrictions. NEOGEN’s cleaner and disinfectant sales significantly declined over the recent months, resulting from lower sales of water treatment products due to COVID-19 restrictions.
Tough Competitive Landscape: NEOGEN faces stiff competition from small businesses as well as large multinational companies. Some of these organizations have substantially greater financial resources than the company. Historically, NEOGEN has faced intense competition resulting from the development of new technologies by the company’s competitors, which could affect marketability and profitability of NEOGEN’s products.
Estimate Trend
NEOGEN has been witnessing a negative estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 1.7% south to $1.17.
The Zacks Consensus Estimate for fourth-quarter fiscal 2021 revenues is pegged at $124.9 million, suggesting a 14.5% rise from the year-ago reported number.
Key Picks
Some other better-ranked stocks from the broader medical space are AmerisourceBergen Corporation , Cantel Medical Corp. and DENTSPLY SIRONA Inc. (XRAY - Free Report) .
Cantel’s long-term earnings growth rate is estimated at 19%. It currently carries a Zacks Rank #2.
DENTSPLY SIRONA’s long-term earnings growth rate is estimated at 20%. It currently carries a Zacks Rank #2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Here's Why You Should Hold on to NEOGEN (NEOG) Stock for Now
NEOGEN Corporation (NEOG - Free Report) is well poised for growth in the coming quarters, backed by its slew of product launches and collaborations. Strong revenues in fiscal third quarter of 2021, along with its impressive international performance, buoy optimism. However, downsides may result from persistent pandemic-led business disruptions and a stiff competitive landscape.
Over the past year, the Zacks Rank #3 (Hold) stock has gained 52.4% compared with 20.6% growth of the industry and 51.7% rise of the S&P 500.
The renowned food and animal safety products provider has a market capitalization of $4.88 billion. The company projects 10% growth for the next five years and expects to maintain strong segmental performance. The company surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average surprise being 0.20%.
Let’s delve deeper.
Strong Q3 Results: NEOGEN’s impressive revenue performance in the third quarter of fiscal 2021 buoys optimism. The company’s segmental performance was primarily boosted by enhanced sales of cleaners and disinfectants to meet requirements created by the coronavirus pandemic. NEOGEN’s international performance was impressive as well, despite the challenging global business climate.
Acquisitions of international distributors and Megazyme, a food-quality diagnostics company, also contributed to growth. Expansion of both margins looks encouraging.
Product Launches: We are upbeat about the slew of product launches by NEOGEN over the recent months. The company, in February, relaunched its popular ThyroKare (levothyroxine sodium tablets), USP, which are approved by the FDA for replacement therapy for diminished thyroid function in dogs. During the same month, the company launched Early Warning COVID-19 Testing for wastewater.
In January, NEOGEN announced the launch of Reveal Q+ for the Aflatoxin M1 test — a faster and easier test to detect the presence of cancer-causing toxin aflatoxin M1.
Partnerships and Acquisitions: We are optimistic about the series of partnership and buyout deals inked by NEOGEN of late. The company, in January, acquired Ireland-based Megazyme, Ltd. — a major supplier of analytical solutions used by quality control laboratories in the global food and beverage industry.
NEOGEN entered into a partnership with Transnetyx, Inc. in November 2020 to collaborate on distribution and advancement of the miniMUGA genotyping array (Mouse Universal Genotyping Array).
Downsides
Persistent Coronavirus Concerns: NEOGEN continues to be adversely impacted by the pandemic-led global market disruptions, especially in the food industry, in some of its important end markets in the United States and Europe due to still-in-place lockdowns and social-distancing restrictions. NEOGEN’s cleaner and disinfectant sales significantly declined over the recent months, resulting from lower sales of water treatment products due to COVID-19 restrictions.
Tough Competitive Landscape: NEOGEN faces stiff competition from small businesses as well as large multinational companies. Some of these organizations have substantially greater financial resources than the company. Historically, NEOGEN has faced intense competition resulting from the development of new technologies by the company’s competitors, which could affect marketability and profitability of NEOGEN’s products.
Estimate Trend
NEOGEN has been witnessing a negative estimate revision trend for 2021. Over the past 90 days, the Zacks Consensus Estimate for its earnings has moved 1.7% south to $1.17.
The Zacks Consensus Estimate for fourth-quarter fiscal 2021 revenues is pegged at $124.9 million, suggesting a 14.5% rise from the year-ago reported number.
Key Picks
Some other better-ranked stocks from the broader medical space are AmerisourceBergen Corporation , Cantel Medical Corp. and DENTSPLY SIRONA Inc. (XRAY - Free Report) .
AmerisourceBergen’s long-term earnings growth rate is estimated at 11.4%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cantel’s long-term earnings growth rate is estimated at 19%. It currently carries a Zacks Rank #2.
DENTSPLY SIRONA’s long-term earnings growth rate is estimated at 20%. It currently carries a Zacks Rank #2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>